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OBJECTIVES: Primary ovarian failure is a rare disorder, and approximately 90% of cases are of unknown
etiology. The aim of this study was to search for mutations in NANOS3, a gene that was recently related to the
etiology of primary ovarian failure, in a group of Brazilian women.
METHODS: We screened for NANOS3 DNA variants in 30 consecutive women who were previously diagnosed
with primary ovarian failure, of unknown etiology and compared the results with those from 185 women with
normal fertility. The NANOS3 gene was amplified by polymerase chain reaction using pairs of specific primers
and then sequenced. The resulting sequences were compared with control sequences available in the National
Center for Biotechnology and Information database.
RESULTS: No mutations in NANOS3 were found in primary ovarian failure patients, but four previously
described polymorphisms were identified at a similar frequency in the control and primary ovarian failure
groups.
CONCLUSIONS: Mutations in NANOS3 were not associated with primary ovarian failure in the present cohort.
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’ INTRODUCTION
Primary ovarian failure (POF), also known as premature
ovarian failure, premature ovarian insufficiency, premature
menopause, or hypergonadotropic hypogonadism, is defined
as the loss of function of the ovaries before age 40 (1). POF
is phenotypically characterized by the triad of primary or
secondary amenorrhea, hypergonadotropic hypogonadism
and hypoestrogenism.
There are several causes of POF, and the genetic causes are
associated with a defect in ovarian development.
Sex determination in mammals is a dynamic and complex
process that requires the interaction of multiple factors, and
both primordial germ cells (PGCs) and somatic cells acquire
sex-specific characteristics.
PGCs are essential for the differentiation and maintenance
of the fetal ovary; when few germ cells enter the genital
ridge during embryogenesis, the supporting lineage cells do
not differentiate, generating strike ovaries (2-4). Because the
differentiation of ovarian somatic cells relies on PGCs, genes
involved in the differentiation and subsequent maintenance
of PGCs are potential candidates for the etiology of 46,XX
gonadal development disorders (5).
Nanos homolog 3 was identified in PGCs of Drosophila, and
the NANOS3 protein has anti-apoptotic activity during the
migration of PGCs toward the gonad (6). Male and female
mice that do not expressNanos3 experience a complete loss of
PGCs during gonadal development (7). The human NANOS3
gene is located on the short arm of chromosome 19 (region 13.13)
and has two exons.
A preliminary study in a Brazilian population identified
a NANOS3 c.385G4A homozygous mutation in two sisters
with POF. In vitro analysis showed that the NANOS3 protein
in these two patients had an impaired ability to prevent the
apoptosis of PGCs, suggesting a possible etiology for the
disorder (8).
Our objective was to search for inactivating NANOS3 muta-
tions in an additional group of 30 women with POF without
apparent cause.
’ MATERIALS AND METHODS
This was a cohort study performed in accordance with the
ethical standards of the Ethics Committee of Hospital das
Clínicas, University of São Paulo School of Medicine, Brazil
(Protocol number 1226/07).DOI: 10.6061/clinics/2016(12)03
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POF was defined as the loss of function of the ovaries
before age 40 (1). We invited 30 consecutive patients with the
diagnosis of POF of unknown etiology who were followed
in the Developmental Endocrinology Unit of Hospital das
Clínicas, São Paulo, Brazil, to undergo screening for NANOS3
mutations. Thyroid, adrenal and ovarian autoimmune dis-
orders, as well as mutations in FSHR, NR5A1, BMP15, GDF9,
GATA4,DMRT1, FOXL2, LHCGR, and STRA8 and premutation
of FMR1, had been ruled out in all these patients. All the
patients had a normal 46,XX karyotype obtained by analysis of
50 metaphases.
Hormonal tests required for the POF diagnosis were
performed at the Laboratory of Hormones and Molecular
Genetics, LIM/42 of the HCFMUSP, using immunofluoro-
metric assays (Delfia, Turku, Finland).
Basal gonadotropin levels were elevated in all patients,
with predominantly high serum FSH levels ranging from 32
to 111 U/L and serum LH levels ranging from 13 to 107 U/L.
Serum estradiol levels were low or within the follicular phase
range in all patients.
The control group was composed of 185 women aged 18 to
65 years, all of whom had normal menstrual cycles and no
history of menopause before 40 years of age or treatment for
subfertility. The control group was screened for the NANOS3
allelic variants found in the POF group.
Genomic DNA was extracted from peripheral blood
leucocytes using the salting out procedure (9). The DNA
concentration and purity were determined using the
NanoPhotometer (Implen GmbH, Schatzbogen, Germany),
considering an ideal 260/280 nm ratio of 1.75, and DNA
integrity was assessed by 1% agarose gel electrophoresis,
staining with SYBR Safe (Invitrogen Life Technologies Cor-
poration, CA, USA) and visualization with ultraviolet light.
NANOS3was amplified by PCR using specific pairs of primers
located in the intronic regions of the gene (Table 1), and the
PCR products were subjected to direct automated sequencing.
We performed PCR amplifications in a total volume of
25 ml (Table 2) as follows:
Exon 1: (94oC - 5 min) x 1 + (94oC - 30 sec; 58oC - 30 sec;
72oC - 45 sec) x 35 + (72oC - 10 min) x 1.
Exon 2: (94oC - 5 min) x 1 + (94oC - 30 sec; 57oC - 30 sec;
72oC - 45 sec) x 35 + (72oC - 10 min) x 1.
The PCR products were analyzed by electrophoresis
on 1% agarose gels stained with SYBR Safe (Invitrogen Life
Technologies Corporation, CA, USA) and visualized with
ultraviolet light. To assess the DNA concentration of the PCR
products, the intensity of the signal emitted by the bands was
compared with the Low DNA Mass molecular weight
marker (Invitrogen, Life Technologies Corporation, CA,
USA). After amplification, PCR products were purified by
incubation with ExoSAP-IT (GE Healthcare Life Sciences,
Buckinghamshire, United Kingdom) for 15 min at 37oC
and then 15 min at 80oC. DNA sequencing was performed
according the protocol of the ABI Prism BigDye Terminator
Cycle Sequencing Ready Reaction Kit (Life Technologies Cor-
poration, CA, USA).
The samples were subjected to direct automated sequen-
cing using the ABI Prism Genetic Analyzer 3130XL (Life Tech-
nologies Corporation, CA, USA). The sequences obtained were
compared to those in the National Center for Biotechnology
Information database (NCBI http://www.ncbi.nlm.nih.gov/).
We performed in silico analysis of the identified variants using
Mutation Taster (available online at http://www.mutationta-
ster.org).
Comparisons between unrelated patients with POF and
controls were performed using contingency tables and w2
analysis for each polymorphism in SigmaStat for Windows
v.3.5. p valueso0.05 were considered statistically significant.
’ RESULTS
NANOS3 mutation screening in 30 unrelated women with
POF of unknown etiology identified the rs897790, rs2016163,
rs369192674 and rs371590850 variants in 18 patients.
The rs897790 variant is located in the 5’ untranslated
region of exon 1, where it caused the replacement of a
cytosine with a thymine at position -23 (c.-23C4T); this
variant was found in 6 patients in the heterozygous state
(Figure 1). In the control group, the rs897790 variant was
identified in 59 women, of whom 54 were heterozygous and
5 were homozygous.
The rs2016163 polymorphism is located in exon 1 and
causes the substitution of an adenine with a guanine at
Table 1 - Sequences of the primers used to amplify NANOS3 exons.
Exon Primer sequence
1 Forward 50 CTG CTC CTC CCT CTT CAC AC 30
Reverse 50 GTC TTC CCC TAA CCC TTG GA 30
2 Forward 50 GTC ACG GGG TCG CTG TCT 3’
Reverse 50 AGT GGG GGC AGT CGT CAT AG 30
Table 2 - PCR amplification protocol for the NANOS3 gene.
Exon H2O (ml) 5X Buffer (ml) dNTP (mM) Forward Primer (pmol) Reverse Primer (pmol) Taq DNA Polymerase (U)
1 16.3 5 0.2 10 10 0.75
2 16.3 5 0.2 10 10 0.75
dNTP: deoxynucleoside triphosphate; ml: microliters; mM: millimolar; pmol: picomoles; U: units.
Figure 1 - A, Electropherogram of a patient with wild type
NANOS3. B, Electropherogram of a patient with the hetero-
zygous rs897790 (c.23C4T) variant, indicated by a black arrow.
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position 354 (c.354A4G). This substitution does not change
the amino acid sequence. Ten of the 30 patients harbored this
polymorphism, one in the homozygous state and 9 in the
heterozygous state (Figure 2). This variant was present in
70 individuals in the control group, of whom 58 were
heterozygous and 12 were homozygous.
Six patients presented with both variants. These pre-
viously identified variants are reported in control databases,
such as the 1000 Genomes Project, at a frequency of greater
than 1%, which classifies them as polymorphisms.
Two patients harbored a GAG duplication at position
512-514 (c.512_514dupGAG) in the transcribed region of
exon 1 (rs369192674). This trinucleotide duplication led to
the addition of a glycine between positions p.171 and p.172
(p.Gly171dup) (Figure 3). In silico analysis of this variant
classified it as not deleterious. This variant is described in
the NCBI database, although its population frequency is not
known. This variant was found in three women in the
control group in the heterozygous state.
Another patient harbored a heterozygous insertion of
18 nucleotides between positions c.134 and c.135 (c.134_
135insGCCGGAGCCGGTGTCAGC) in the transcribed region
of exon 1 (rs371590850). This insertion leads to the addition of
six amino acids between positions p.45 and p.46 (p.Ala45_
Leu46insProGluProValSerAla) (Figure 4). In silico analysis
classified this variant as not harmful. This variant is described
in the NCBI database, although its population frequency is not
known. In the control group, this variant was identified as
heterozygous in 6 women.
The screening results for the rs897790, rs2016163, rs3691
92674 and rs371590850 variants in the control and POF
groups are summarized in Table 3.
The allele distributions of the rs897790, rs2016163,
rs369192674 and rs371590850 variants were not significantly
different between the POF patients and the control group
(p=0.271, p=0.787, p=0.295 and p=0.597, respectively) (Table 3).
We did not identify any deleterious NANOS3 variants in
the studied population.
’ DISCUSSION
In the present study, we screened for NANOS3 muta-
tions in a cohort of women with POF and identified only
four previously described variants, which were detected at a
similar frequency in the control group.
Although most POF cases are sporadic, 10-15% are
familial, corroborating the hypothesis that this disorder has
a genetic component. However, despite recent advances in
molecular biology, approximately 90% of POF cases are of
unknown etiology (1,10). The role of NANOS3 in inhibit-
ing the apoptosis of PGCs and thus contributing to their
maintenance makes this protein a natural candidate for the
etiology of POF in humans (11). Loss of NANOS3 function
may lead to PGC death: Nanos3 knockout mice do not have
PGCs (7). Based on this finding, three groups used Sanger
sequencing to screen women with POF for NANOS3 muta-
tions (8,12-14). Qin et al. studied samples from 80 Chinese
Figure 2 - A, Electropherogram of a patient with wild type
NANOS3. B, Electropherogram of a patient with the hetero-
zygous rs2016163 (c.354A4G) variant, indicated by a black arrow.
Figure 3 - A, Electropherogram of a patient with wild type
NANOS3. B/C, Electropherogram of a patient heterozygous for
the rs369192674 (c.512_514dupGAG) variant. The overlapping
sequences of the two alleles, wild type and variant, are shown
beginning at the black arrow.
Figure 4 - A, Electropherogram of a patient with wild type
NANOS3. B, Electropherogram of the patient with the hetero-
zygous rs371590850 (c.134_135insGCCGGAGCCGGTGTCAGC) var-
iant. The overlapping sequences of the two alleles, wild type and
variant, are shown beginning at the black arrow.
Table 3 - Distribution of NANOS3 variants in the control and
patient groups.
Allelic Variant POF Group Control Group p#
rs897790 6*/30** 59*/185** 0.271
rs2016163 10*/30** 70*/185** 0.787
rs369192674 2*/30** 3*/185** 0.295
rs371590850 1*/30** 6*/185** 0.597
POF: Premature Ovarian Failure.
* : number of individuals with the variant; **: total number of individuals;
#: Chi-square test; po0.05 indicated significance.
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and 88 Caucasian women by denaturing high-performance
liquid chromatography (DHPLC), followed by Sanger seq-
uencing, and did not identify any causative mutations in
NANOS3 (12). Wu et al. evaluated 100 Chinese patients with
POF and reported a heterozygous p.Arg153Trp mutation in
NANOS3 in a 23-year-old patient born from consanguineous
parents. Transfection assays in HEK293 cells showed that the
half-life of the mutant p.Arg153Trp protein was significantly
reduced. Using an animal model, these researchers also
showed that the PGC population was directly related to
NANOS3 protein levels. Together, these two findings impli-
cate the c.457C4T mutation (p.Arg153Trp) in the etiology of
POF in this patient (13).
Finally, a previous study in a Brazilian cohort evaluated
85 patients with primary or secondary ovarian failure
and reported the novel homozygous c.358G4A mutation
(p.Glu120Lys) in NANOS3 in two sisters with POF. In vitro
analysis showed a significant loss of PGC viability, and
in silico modeling of mutant NANOS3 suggested that this
amino acid change might destabilize the protein-RNA inter-
action. This evidence supports the hypothesis that the
c.358G4A mutation, which increases the apoptosis rate of
PGCs during the embryonic period, is the etiological factor
for POF in these two patients (8).
Considering these three studies involving the index case of
343 families, the NANOS3 mutation frequency in POF is less
than 0.5% (8,12-14).
Our study included 30 additional Brazilian women with
POF, but no mutations were found in the NANOS3 gene. The
four variants that were identified in the present study have
already been described, but only the rs897790 and rs2016163
variants were previously reported in POF women (8,12,13).
The rs2016163 variant was also identified in normal women
by Qin et al. (12). No significant difference was observed in
the allele frequencies of the rs897790, rs2016163, rs369192674
and rs371590850 variants between POF patients and the
control group. Our negative results should be interpreted
cautiously due to the small number of patients; POF is a rare
disorder. In addition, only the NANOS3 coding regions and
exon boundaries, not the intronic and regulatory regions,
were sequenced.
In conclusion, despite the prominent role of NANOS3 in
ovarian development, our findings suggest that NANOS3
mutations were not associated with POF in the present cohort.
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